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Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature
myeloid cells that accumulate during pathological conditions such as cancer and are asso-
ciated with a poor clinical outcome. MDSC expansion hampers the host anti-tumor immune
response by inhibition of T cell proliferation, cytokine secretion, and recruitment of regula-
toryT cells. In addition, MDSC exert non-immunological functions including the promotion
of angiogenesis, tumor invasion, and metastasis. Recent years, MDSC are considered as a
potential target in solid tumors and hematological malignancies to enhance the effects
of currently used immune modulating agents. This review focuses on the characteris-
tics, distribution, functions, cell–cell interactions, and targeting of MDSC in hematological
malignancies including multiple myeloma, lymphoma, and leukemia.
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INTRODUCTION
It has been widely accepted that the bone marrow (BM) microen-
vironment becomes immunosuppressive and plays a crucial role in
cancer development and progression (1, 2). Immune suppression
is caused by inhibition of activated immune cells, and genera-
tion or expansion of immunosuppressive cell types. Regulatory
T cells, myeloid-derived suppressor cells (MDSC) and tumor-
associated macrophages (TAM) all contribute to an immuno-
logically permissive microenvironment for cancer cells (2–4).
MDSC are generally defined as a heterogeneous cell population
that arises from myeloid progenitor cells in the BM. These prog-
enitor cells have the capacity to differentiate into macrophages,
dendritic cells (DC), or granulocytes, or remain in an undifferen-
tiated state (defined as MDSC) (5, 6). In healthy mice, immature
myeloid cells are present in the BM and in small numbers in
the spleen; however, they highly accumulate in spleen, lymph
nodes, and tumor tissue of tumor-bearing mice (6–8). MDSC
are increased in solid tumors (e.g., breast cancer, colorectal can-
cer) as well as hematological malignancies [e.g., multiple myeloma
(MM), leukemia, and lymphoma] (9–14). MDSC expansion and
activation is promoted by tumor cells as well as their microenvi-
ronment, mainly by the secretion of cytokines and growth factors
(8). For mice, MDSC are characterized based on dual expression
of CD11b and GR1. Furthermore, MDSC are subdivided into
Ly6Glow (monocyte morphology, MO-MDSC) and Ly6Ghigh cells
(polymorphonuclear morphology, PMN-MDSC, or G-MDSC) (5,
6, 15). Human MDSC express the myeloid markers CD11b and
CD33. CD14+HLA-DRlow/− MDSC are mainly described as the
monocytic subpopulation, while human granulocytic MDSC are
mostly defined to be CD15+ (16). MDSC inhibit innate and adap-
tive immunity by regulatory T cell activation and secretion of nitric
oxide (NO), reactive oxygen species (ROS), and immunosuppres-
sive cytokines (e.g., IL-10) (6, 17). They not only affect the immune
system but also promote tumor angiogenesis, tumor cell invasion,
and metastasis. A more extensive description of the phenotype
and functional mechanisms of MDSC in general is available in
previous reviews (8, 18–20). In the last years, efforts have been
made to unravel the characteristics, distribution, and function of
murine and human MDSC in hematological malignancies as illus-
trated in Table 1 and Figure 1. This will be summarized in this
review.
MDSC IN MULTIPLE MYELOMA
Multiple myeloma is a malignant plasma cell disorder character-
ized by the accumulation of neoplastic plasma cells in the BM
and the presence of monoclonal immunoglobulins in the blood
and/or urine. Clinical features of this disease include anemia, bone
pain, renal failure, frequent occurrence of infections, and hyper-
calcemia (27). A hallmark of MM is the reciprocal interaction
between tumor cells and the BM microenvironment, resulting in
accelerating bone loss, increased blood vessel formation, and pro-
gressive cancer growth (28). MM is the second most common
hematological malignancy and constitutes 1% of all cancers and
13% of all hematological cancers. It affects mostly elderly patients
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Table 1 | General overview of MDSC phenotype.
Species Disease/
condition
Markers MDSC subtypes Reference
Murine MM CD11b+GR1+ Ly6Glow or
MO-MDSC
(10, 21, 22)
Lymphoma Ly6Ghigh or G-MDSC
Leukemia
Human MM CD11b+CD33+ CD14+HLA-DR−/low
or MO-MDSC
(23)
CD14−CD15+ or
G-MDSC
(12, 22)
Lymphoma – CD14+HLA-DRlow (14)
Leukemia CD11b+CD33+ CD14−HLA-DR (AML) (24)
CD14−arginase-1+
(CML)
(25)
CD14+HLA-DRlow
(CLL)
(13)
Allo-HSCT – CD14+HLA-DRlow (26)
Markers described to characterizemurine and humanMDSC inmultiple myeloma
(MM), lymphoma, leukemia and allogeneic hematopoietic stem cell transplanta-
tion (Allo-HSCT).
(the median age of diagnosis is 67 years), though 3% of all MM
patients are under the age of 40 years. The survival of patients
has been improved by new agents like the proteasome inhibitor
bortezomib and the immune modulating drug lenalidomide in
combination with the alkylating agent melphalan and dexametha-
sone (29). Despite this evolution, patients still relapse or become
refractory to treatment, indicating the need for new therapies.
IMMUNE DYSFUNCTION IN MM
Immune dysfunction is an important feature of MM patients
and leads to infections and increased tumor growth. A variety of
immune defects are observed in MM including cellular abnormal-
ities (e.g., B cells, T cells, DC), secretion of immunosuppressive
cytokines (e.g., TGF-β, VEGF, HGF), and increased frequencies
of immunosuppressive cell types (including regulatory T cells
and MDSC) (30, 31). B-cells derived from MM patients showed
impaired immunoglobulin synthesis and secretion (32). There-
fore, intravenous administration of immunoglobulin has been
used to restore the antibody-mediated immunity in patients with
hypogammaglobulinemia (33). Besides B-cell defects, the T cell-
mediated immunity is also impaired in MM patients. CD4+ T
cells and in particular T-helper 2 cells (Th2) were significantly
decreased in MM patients, while no difference in CD8+ T cell
number could be observed (34, 35). Furthermore, MM cells are
able to directly target T cells by Fas/Fas ligand interaction (36).
Dendritic cells are antigen-presenting cells (APC) responsi-
ble for the induction of T cell responses. Although controversy
remains about the number of DC in MM patients, it has been
clear that they are functionally impaired. They show a lower
expression of human leukocyte antigen (HLA) molecules and a
reduced capacity in stimulating T cell proliferation and cytokine
production (37). Furthermore, MM cells inhibit DC function by
secretion of distinct cytokines including IL-6, IL-10, and TGF-β
(38, 39).
Natural killer T cells (NKT) belong to the innate immune sys-
tem and show important defects in MM patients. They not only
decrease in cell number at the end-stage of the disease but it has
been hypothesized that tumor-derived glycolipids also lead to a
deficiency in IFNγ production and NKT dysfunction (40, 41).
Immune responses are also hampered by immunosuppressive
cell types including regulatory T cells and TAM. TAM (CD68+)
are increased in the BM of MM patients and promote cancer
cell proliferation, angiogenesis, and drug resistance. In addition,
TAM show a poor antigen-presenting capacity and inhibit T cell
proliferation (42). Increased frequencies of regulatory T cells
(CD4+CD25highFoxP3+) could also be observed in peripheral
blood and BM of MM patients (43).
The development of immune modulating agents (IMiDs)
including thalidomide, and its more potent and less toxic deriva-
tives lenalidomide and pomalidomide, have made an important
impact on treatment of relapsed/refractory MM patients (44).
The exact molecular mechanism of IMiDs is not fully understood
but broadly they affect the immune response by increasing T cell
proliferation, NK cell-mediated lysis, and reducing regulatory T
cells. Furthermore, IMiDs decrease bone resorption and angio-
genesis (45, 46). Cellular immunotherapy, which is based on a
graft-versus-myeloma effect (e.g., donor lymphocyte infusions,
dendritic cell vaccines) showed promising results if utilized for
relapsed or persistent MM after allogeneic stem cell transplan-
tation (SCT) (47). However, immunosuppressive cell types limit
the effectiveness of immunotherapy, indicating the importance of
regulatory T cell, TAM and MDSC targeting in combination with
current anti-myeloma drugs.
MDSC CHARACTERIZATION AND DISTRIBUTION IN MM
In our lab, MDSC were investigated using the 5T2 and
5T33MM mouse models. These models are derived from elderly
C57BL/KaLwRij mice that spontaneously developed MM and are
maintained by intravenous transfer of cancer cells into young syn-
geneic mice. Both models are immunocompetent and resemble
the human disease closely as MM cells are able to grow in the
surrounding BM microenvironment. The 5T33MM model has a
more rapid growth (3 weeks), while the 5T2MM model is char-
acterized by a moderate growth (12 weeks) and osteolytic bone
lesions (48). In the BM, a clear shift toward a CD11b+Ly6Glow
population, typically considered to be the phenotype of MO-
MDSC, was observed at the end-stage of the disease in the 5T2 and
5T33MM mice (10). In addition, in this MO-MDSC population,
we could discriminate different MDSC subsets based on differen-
tial Ly6C expression: inflammatory monocytes (Ly6ChighSSClow),
eosinophils (Ly6CintermediateSSChigh), and immature myeloid cells
(Ly6CintermediateSSClow). All of these populations may contribute
to T cell suppression, with the monocytes being the most potent.
Especially, a major increase in immature myeloid cells could be
observed in the BM of the 5T33MM mouse model, indicat-
ing a differentiation block in the presence of MM cells (10).
Of note, circulating CD11b+ cells increased only at the end-
stage of the disease (data unpublished). In the similar 5TGM1
model, MDSC expansion in the blood, BM and spleen could also
Frontiers in Oncology | Hematology Oncology December 2014 | Volume 4 | Article 349 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De Veirman et al. MDSC in hematological malignancies
FIGURE 1 | General overview of MDSC immunosuppressive
mechanisms and expansion in hematological malignancies and
during stem cell transplantation (SCT). (A) MDSC suppress the
immune system by distinct mechanisms including increased macrophage
differentiation and regulatory T cell (Treg) proliferation, direct actions of
MDSC on T cells by increased NO, nitrotyrosine and ROS secretion, and
decreased l-arginine production. (B) MDSC originate from common
myeloid progenitors (CMP), which arise from hematopoeitic stem cells
(HSC). M-MDSC and G-MDSC are formed and proliferate in the presence
of distinct factors including GM-CSF, IL-6, VEGF, and IL-1β. Factors involved
in the proliferation and survival of MDSC are S100A9, Cyclin D1, Bcl-xL
Myc, and Survivin.
be observed up to 28 days after MM cell inoculation (21). In
another immunocompetent mouse model, tumor cell lines derived
from transgenic Bcl-xl/Myc mice (ATLN and DP42) were intra-
venously injected into syngeneic mice (22). A clear increase in
BM MDSC (CD11b+GR1+) was shown the first week after MM
cell inoculation with a similar increase in both MO-MDSC and
G-MDSC subsets. The BM is the primary tumor site for MM
cells and also the site where MDSC are generated. The direct
contact of the cancer cells with myeloid progenitor cells might
explain the early MDSC conversion and accumulation. During
disease progression, MM cells take over the BM microenviron-
ment and disturb and replace normal hematopoiesis. Therefore,
the absolute number of MDSC in the BM initially increases, but
then gradually decreases at later stages of disease, as observed in
the 5T33MM model (data unpublished) and in the ATLN and
DP42 models (22).
Some controversy exists about the MDSC characterization
markers in MM patients. Brimnes and colleagues were the first
to describe an increase of CD14+HLA-DR−/low MO-MDSC in
peripheral blood of MM patients at diagnosis compared to
healthy donors (23). In contrast, recent studies demonstrated
no difference in the MO-MDSC population, but a significant
increase in G-MDSC, defined as CD11b+CD14−CD33+CD15+
(22) or CD11b+CD14−CD33+CD15+HLA-DRlow (12), in BM
and peripheral blood of MM patients. Different flow cytometry
analyses, limited patient numbers and distinct treatment regi-
mens of MM patients could explain the discrepancy of the results
(Table 1).
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MDSC EXPANSION AND MECHANISMS IN MM
Little is known about the mechanisms of MDSC expansion,
differentiation, and activation in MM. Although no specific
studies in MM are conducted, distinct factors present in the
MM microenvironment or secreted by MM cells are able to reg-
ulate MDSC expansion and activation. Possible factors include
IL-6, GM-CSF, VEGF, and IL1β, which are mainly secreted by the
myeloma BM microenvironment (49–51). STAT3 has been iden-
tified as the main transcription factor for MDSC expansion in
distinct cancer models and the expression of the STAT3 target
genes cyclin D1, MYC, survivin, and Bcl-xL, resulted in increased
survival and proliferation. In addition, the myeloid-related pro-
teins Arginase-1, S100A8, and S100A9 are upregulated by STAT3
(8, 52). S100A9 knockout (KO) mice showed a decrease in imma-
ture myeloid cells and a potent anti-tumor immune response
(53). Importantly, a delay in the development of ovalbumin-
expressing MM tumors was observed in S100A9KO mice com-
pared to wild-type (WT) mice. Adoptive transfer of MDSC derived
from WT-MM-bearing mice into S100A9KO MM mice resulted in
a reduced survival (22), clearly demonstrating the importance of
MDSC-derived S100A9 in MM (Figure 1B).
IMMUNOSUPPRESSIVE FUNCTION OF MDSC SUBSETS IN MM
In the 5TMM as well as in the ATLN model, MDSC derived from
MM-bearing mice showed clear immunosuppressive activity com-
pared to immature myeloid cells from naïve mice (10, 22). In
the 5TMM model, MO-MDSC were more potent to inhibit T
cell proliferation compared to G-MDSC. Different subsets in the
MO-MDSC population (inflammatory monocytes, eosinophils,
and immature myeloid cells) contribute to immunosupression,
with inflammatory monocytes being described as the most potent
inhibitors. Moreover,myeloma-derived MDSC showed an upregu-
lation of iNOS, arginase-1, and IL-10, compared to MDSC derived
from naïve mice. The immunosuppressive action of MO-MDSC
was partially abrogated by inhibition of iNOS by l-NMMA,
while an arginase-1 inhibitor (norNOHA) did not affect T cell
proliferation (10) (Figure 1A).
In human experiments,both MO-MDSC (CD11b+CD14+HLA-
DR−/low) and G-MDSC (CD11b+CD14−CD33+CD15+) were
sorted from BM of MM patients and significantly suppressed T
cell activity in vitro. In contrast, immature myeloid cells derived
from healthy donors did not exert any immunosuppressive activ-
ity (22). Görgün et al. described strong suppressive activities of
MDSC on CD8+ T cells and NKT. As a control, they demonstrated
that APC (CD11b+CD14+HLA-DR+) were able to increase T
cell proliferation in vitro. However, this was in contrast with a
recent study where both CD14+HLA-DRlow and CD14+HLA-
DRhigh cells derived from MM patients exerted immunosuppres-
sive capacities (54). As observed in mice, specific inhibitors of
arginase-1 and iNOS partially abrogated the immunosuppressive
function of human MDSC (12).
MDSC AS OSTEOCLAST PROGENITORS IN MM
Besides their role in immune suppression, MDSC also play a piv-
otal role in bone disease. MDSC are macrophage progenitors
which are able to differentiate into osteoclasts. MDSC derived
from myeloma-bearing mice had a higher potential to differentiate
into mature and functional osteoclasts in vitro and in vivo com-
pared to MDSC from control mice. Co-inoculation of 5TGM1
MM cells and MDSC resulted in increased tumor burden and
bone lesions. In addition, in vivo treatment with zoledronic acid,
a potent nitrogen-containing bisphophonate, was able to induce
a 30% reduction in MDSC (CD11b+GR1+) number, associ-
ated with a decrease in osteoclastogenesis to control levels (21).
Interestingly, it has been shown that not all MDSC populations
were able to differentiate into osteoclasts. Sawant et al. stud-
ied breast cancer MDSC derived from lung, blood, spleen, and
lymph nodes and observed no osteoclastogenesis when cells were
derived from these organs. However, BM MDSC from tumor-
bearing mice underwent osteoclast differentiation in contrast to
BM MDSC of naïve mice. Although factors responsible for this
phenomenon need to be identified, a variety of osteoclastogenic
growth factors including RANTES and MCP-1 are secreted by
breast cancer cells (55). Although the early idea of MDSC is that
they are blocked in their differentiation potential, it seems that
in cancers involving bone disease, MDSC can differentiate into
osteoclasts.
MDSC IN LYMPHOMA
MDSC CHARACTERIZATION AND DISTRIBUTION IN LYMPHOMA
Lymphoma originates in the lymphatic system and is charac-
terized by abnormal proliferation of B cells and T cells, mostly
classified in Hodgkin and non-Hodgkin lymphoma. EG7 and
EL4 are two well-characterized subcutaneous lymphoma models
that are frequently used to investigate the MDSC subpopula-
tions and functions. MO-MDSC (Ly6G−SSClow) and G-MDSC
(Ly6G+SSChigh) accumulated equally in the spleen of EL4 and EG7
murine models (5, 6). Furthermore, the majority of Ly6G− cells
showed increased F4/80 expression. Interestingly, three markers
were differentially expressed in naïve and tumor-induced mono-
cytes including CD71, CD115, and CD80, indicating a distinct
MDSC phenotype in tumor-bearing mice compared to naïve mice
(5, 6). Shlecker et al. investigated MDSC distribution in RMA-S
lymphoma-bearing mice and found that MO-MDSC as well as
G-MDSC accumulated in blood, spleen, and tumor tissue (56).
Little is known about the presence and characteristics of
MDSC in human lymphoma patients. In B-cell non-Hodgkin
lymphoma (NHL), peripheral blood mononuclear cells (PBMC)
showed a reduced Th1-response as determined by IFNγ pro-
duction compared to healthy controls. Furthermore, less T cell
proliferation was observed after coincubation of PBMC with
monocytes derived from NHL patients. Importantly, mono-
cyte depletion by anti-CD14 immunomagnetic beads resulted
in restored T cell proliferation. It has been shown that NHL
monocytes had impaired STAT1 phosphorylation and IFNα pro-
duction upon CpG oligodeoxynucleotides stimulation and defects
in dendritic cell differentiation. No difference in the percent-
age of monocytes in peripheral blood of NHL patients could be
detected compared to healthy controls; however, a clear shift in
HLA-DR expression was observed. CD14+ monocytes in NHL
patients showed a significant decrease in HLA-DR expression,
which was correlated with suppressed immune functions and
a more aggressive disease. In addition, elevated arginase-1 lev-
els could be detected in plasma of NHL patients. Furthermore,
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NHL PBMC proliferation was increased by exogenous l-arginine
administration in vitro, indicating that the arginine metabolism
is at least partially responsible for the immunosuppressive effects
(14) (Table 1).
MDSC EXPANSION AND DIFFERENTIATION IN LYMPHOMA
Different factors contribute to MDSC expansion and differen-
tiation in lymphoma models. Adiponectin has been identified
as an important regulator of MDSC expansion in EL4 T cell
lymphoma-bearing mice. Tumor-bearing adiponectin knockout
(APNKO) mice showed reduced levels of splenic MDSC com-
pared to WT mice and a higher amount of NK and CD8+ T cells.
These effects were associated with reduced lymphoma growth in
APNKO mice. In addition, this study demonstrated that G-CSF
was lower expressed in tumor-bearing APNKO mice and that this
factor played a key role in MDSC differentiation (57). Dardalhon
and colleagues described a role for the Tim3-Galectin-9 pathway
in MDSC proliferation. EL4 mice treated with anti-Tim3 antibod-
ies showed a delayed tumor progression and a lower frequency
of CD11b+GR1+ cells. The authors hypothesized that Tim3 on
IFNγ-secreting T cells interact with galectin-9 expressed by MDSC
and that this ligand/receptor interaction is involved in MDSC
expansion and function (58). Interestingly, galectins have been
identified as important modulators of monocyte and macrophage
function. Galectin-1 positively correlated with the M2 macrophage
marker CD163, while galectin-3 was highly secreted by activated
M2 macrophages (59, 60). TAM predict a poor clinical outcome
in classical Hodgkin’s lymphoma patients and galectin-1 has been
identified as a potential biomarker for relapsed/refractory disease
(60, 61).
Besides the ability of immature myeloid cells to rapidly differ-
entiate into macrophages and DC in vitro, Youn and colleagues
observed a preferential differentiation of MO-MDSC toward G-
MDSC in EL4 tumor-bearing mice (62). MO-MDSC acquire
morphological, phenotypical, and functional features of G-MDSC
in tumor-bearing mice including a high ROS production and
myeloperoxidase activity. Acquisition of the granulocytic pheno-
type was mediated by epigenetic silencing of the retinoblastoma
gene by HDAC2. Schlecker et al. characterized tumor-infiltrating
MDSC subpopulations in the RMA-S T cell lymphoma model.
Interestingly, tumor-derived MO-MDSC showed increased lev-
els of CCR5 ligands (CCL3, CCL4, and CCL5), which were also
associated with regulatory T cell recruitment (56). Serafini and
colleagues demonstrated a role for MDSC in regulatory T cell
proliferation in the A20 B-cell lymphoma mouse model. They
characterized MDSC as APC, which were able to expand regula-
tory T cells (FOXP3+CD4+) from a preexisting regulatory pool
and not by T cell conversion. Furthermore, they demonstrated
IL4Rα is expressed on MDSC and correlates with tumor progres-
sion. In vivo treatment with sildenafil reduced regulatory T cell
expansion and prevented T cell anergy (63).
As observed in MM models, S100A9 protein has been described
as an important regulator of MDSC expansion. Tumor-derived
conditioned medium induced accumulation of MDSC and
reduced dendritic cell differentiation. This was accompanied
by increased S100A8 and S100A9 expression. S100A9KO mice
injected with EL4 lymphoma cells resulted in a smaller tumor
size or even tumor rejection. T cells derived from S100A9KO
mice showed higher cytotoxicity against EL4 compared to T
cells derived from WT mice. In addition, S100A9 overexpres-
sion in hematopoietic stem cells resulted in reduced dendritic cell
and macrophage differentiation and accumulation of immature
myeloid cells (53). Kälberg et al. demonstrated that the interaction
between S100A9 and toll like receptor 4 (TLR4) promoted tumor
growth (64). Quinoline-3-carboxamides or Q compounds (e.g.,
Tasquinimod) were able to block this interaction and inhibited
tumor proliferation (65).
Recently, it has been demonstrated that accumulation of MDSC
in tumor-bearing EL4 mice was not caused by increased survival
of these cells. As a matter of fact, MDSC in tumor-bearing mice
have a shorter lifespan than monocytes and neutrophils, but are
rapidly replaced by new cells as determined by in vivo BrdU label-
ing and apoptosis assays. ER stress, present in tumor-bearing mice,
causes TNF-related apoptosis-induced ligand receptors (TRAIL-
R) upregulation in MDSC. The expression of DR5, a TRAIL-R, was
significantly higher in MDSC derived from tumor-bearing mice
compared to control mice. Furthermore, MDSC derived from DR5
KO mice showed increased survival compared to WT MDSC. Data
clearly demonstrated that inhibition of DR5 improved CD8+ T cell
responses in mice bearing TRAIL-insensitive tumors. For cancer
patients, a decrease in survival of G-MDSC compared to granulo-
cytic cells was observed. In addition, agonistic DR5 antibodies as
well as TRAIL-recombinant protein was able to induce apoptosis
of G-MDSC. Although no difference in DR5 expression between
G-MDSC and granulocytic cells could be observed in patients, a
lower expression of TRAIL decoy receptors 1 and 2 was determined
(66) (Figure 1B).
IMMUNOSUPPRESSIVE FUNCTION OF MDSC SUBSETS IN LYMPHOMA
Different lymphoma models have been employed to study MDSC
biology. The advantage of the immunogenic mouse BW-Sp3 thy-
moma is the existence of tumor progressors and regressors within
the same model. The majority of the mice develop a tumor-specific
CD8+ T cell response resulting in tumor regression but a signifi-
cant fraction of the tumors ultimately start to progress. By studying
mice with different tumor outcomes, a significant contribution of
splenic CD11b+ GR1+ cells to the immune dysregulation seen
in tumor progressors could be demonstrated. Indeed, while T-cell
activating APC were induced in the spleen of regressors, T cell sup-
pressive MDSC were increased in the spleen of progressors. These
MDSC, in particular the MO-MDSC fraction, could differentiate
into macrophages that had very high arginase levels and expressed
high levels of M2-associated genes, suggesting that MDSC could be
precursors of M2-oriented and immunosuppressive macrophages
(15, 67). Interestingly, stimulation of the nuclear hormone recep-
tor PPARγ, one of the M2-associated markers, diminished the
suppressive potential of these MDSC-derived macrophages (15).
Also MO-MDSC and G-MDSC derived from EL4 and EG7
lymphoma models demonstrated immunosuppressive capacity
in vitro (5, 6). While G-MDSC showed a higher ROS produc-
tion, MO-MDSC had increased expression of NO and nitrotyro-
sine. l-NMMA (NO inhibitor) and arginase inhibitors were able
to partially reverse MO-MDSC suppression. Suppressive activ-
ities of G-MDSC could be diminished by catalase, a hydroxyl
www.frontiersin.org December 2014 | Volume 4 | Article 349 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De Veirman et al. MDSC in hematological malignancies
peroxide inhibitor. Employing mice deficient for IFNγR or for
the transcription factors downstream of IFNγR – STAT1 and
IRF-1, it was demonstrated that EG7 lymphoma-induced MO-
MDSC needed to be stimulated by IFNγ to become suppressive
and that the suppressive mechanism was mediated by parallel
IRF-1/iNOS-dependent and IRF-1/iNOS-independent pathways
(68). G-MDSC only minimally depended on IFNγ and iNOS for
their suppressive activity (68). Kusmartsev et al. investigated the
induction of T cell tolerance by immature myeloid cells from
lymphoma-bearing mice in vivo (69). They adoptively transferred
transgenic T cells specific for OVA-derived peptide and imma-
ture myeloid cells from EG7 tumor-bearing mice into naïve mice.
Afterward, lymph node cells were isolated and they observed a dra-
matically reduced or eliminated antigen-specific T cell response
after adoptive transfer of immature myeloid cells. Importantly,
GR1+ cells from naive mice and DC from EL4 tumor-bearing
mice were not able to inhibit T cell responses. In addition, it
has been demonstrated that immature myeloid cells take up sol-
uble protein in vivo, process the protein, and present antigenic
epitopes on their surface to induce T cell anergy. Nagaraj et al.
subsequently demonstrated that the incubation of MDSC with
Ag-specific CD8+ T cells caused nitration of the molecules on the
surface of CD8+ T cells that are localized to the site of physical
interaction between MDSC and T cells. This process induces CD8+
T cell tolerance that is only specific for the peptide presented by the
MDSC. MDSC caused dissociation between the antigen-specific
TCR and CD3zeta molecules, disrupting TCR complexes on T cells
(70). This is in accordance with the fact that EG7-derived MDSC
decreased antigen-driven CD8+ T cell proliferation in vitro, while
anti-CD3-driven proliferation was not affected, again indicating
an antigen-specific suppression. Our own studies demonstrated
that EG7 lymphoma-induced MDSC intricately influence differ-
ent CD8+ T cell activation events, whereby some parameters are
suppressed while others are stimulated (68). For example, while
CD8+ T cell proliferative capacity and IL-2 secretion are clearly
diminished in the presence of MDSC, the IFNγ production by
these cells is actually stimulated on a per cell basis. Complex effects
of MO- and G-MDSC on CD8+ T cell adhesiveness to the extra-
cellular matrix and to selectins, on sensitivity to FasL-mediated
apoptosis and on cytotoxicity were also noted (Figure 1A).
MDSC IN LEUKEMIA
Leukemia is characterized by abnormal proliferation of imma-
ture white blood cells that usually starts in the BM. Four
main types of leukemia are defined: acute myeloid leukemia
(AML), chronic myeloid leukemia (CML), acute lymphoblas-
tic leukemia (ALM), and chronic lymphocytic leukemia (CLL).
Studies on MDSC in leukemia are limited. At diagnosis, periph-
eral blood of AML patients showed a high heterogeneity in
MDSC percentage (CD14−HLA-DR−CD33+CD11b+) and a
negative correlation with CD34 percentage (24). Christians-
son et al. demonstrated increased MDSC numbers, pheno-
typed by CD11b+CD14−CD33+, and arginase-1 expression in
CML patients (25). In untreated CLL patients, the circulating
CD14+HLA-DRlow cells were increased compared to healthy con-
trols. In addition, these cells were positive for myeloid markers
(CD33, CD11b, CD13, CD11c) and expressed the macrophage
colony-stimulating factor receptor CD115 and IL4α receptor,
which are associated with MDSC activity. MDSC suppressive
capacity in vitro was demonstrated and linked to indoleamine 2,3-
dioxygenase (IDO) expression. Furthermore, MDSC promoted
regulatory T cell development indicating a cross-talk between CLL
cells, MDSC, and regulatory T cells (13). MDSC markers described
in literature for MM, lymphoma, and leukemia are summarized in
Table 1.
Besides the observations illustrating the importance of MDSC
and regulatory T cells in T cell tolerance, it has to be remarked that
T cell dysfunction can also be independent of these immunosup-
pressive cell types. Zhang and colleagues observed T cell dysfunc-
tion in a murine model for AML, which was antigen-specific and
could not be reversed after MDSC or regulatory T cell depletion.
It has been argued that T cell tolerance in that case is regulated by
tolerogenic APC. Consequently, T cell activation and prolonged
survival could be achieved by the use of agonistic anti-CD40
antibodies, which induces immunogenic DC (71).
MDSC TARGETING STRATEGIES IN HEMATOLOGICAL
MALIGNANCIES
MDSC could be considered as a valid therapeutic target since they
contribute to distinct processes in tumor development, progres-
sion and metastasis (18, 72). MDSC targeting can be achieved by
distinct strategies including MDSC depletion, MDSC deactivation,
induction of maturation/differentiation, and a block in MDSC
development (18, 73). Currently used MDSC targeting drugs are
listed in Table 2.
MDSC DEACTIVATION
MDSC suppressive mechanisms are often associated with the l-
arginine metabolism, which has been extensively reviewed (8,
18, 77). Activated MDSC express high amounts of arginase-
1 and NOS2, and inhibitors of both enzymes (L-NMMA for
NOS2 and norNOHA for arginase-1) reversed MDSC sup-
pressive mechanisms in MM and lymphoma models (10, 12,
68). Phosphodiesterase (PDE5) inhibitors (such as Sildenafil)
inhibit cyclic guanosine monophosphate (cGMP) degradation and
reduce arginase-1 and NOS2 expression. It has been hypoth-
esized that high levels of cGMP interfere with the IL4Rα
expression by MDSC, resulting in reduced levels of arginase-
1 and NOS2. Consequently, Sildenafil treatment of peripheral
blood mononuclear cells isolated from MM patients resulted
in increased T cell proliferation in vitro (74). Another PDE5
inhibitor, Tadalafil, entered a phase II clinical trial to improve
the response to dexamethasone and lenalidomide in 13 MM
patients who were refractory to lenalidomide. However, the
study was stopped due to a lack of response (75). Recently,
the group of Borello et al. demonstrated a reduction in M-
spike by Tadalafil treatment in an end-stage relapsed/refractory
MM patient. BM CD14+ cells decreased over time by Tadalafil
treatment. This was associated with a decrease in IL4Rα, iNOS,
and arginase-1 expression in MDSC. BM nitrosylation was also
decreased and T cell activity enhanced upon Tadalafil administra-
tion (76).
The tryptophan-degrading enzyme IDO is synthesized by
MDSC and contributes to immune tolerance by mediating T
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Table 2 | General overview of MDSC targeting agents.
Targeting
strategy
Mechanims of
action
Example(s) Reference
MDSC
deactivation
Phosphodiesterase
(PDE5) inhibitors
Tadalafil
Sildenafil
(74–76)
NO inhibitors L-NAME (10, 12, 77)
Nitroaspirin
COX2 inhibitors Celecoxib (78)
Arginase inhibitors NOHA (10, 12)
L-NAME
ROS inhibitors Synthetic triterpenoids
(e.g., Bardoxolone
methyl)
(79)
IDO inhibitors D,L-1-methyl-
tryptophan
(80)
MDSC
depletion
Cytotoxic agents 5-Fluorouracil
Gemcitabine
(81)
HSP90 inhibitors 17-DMAG (82)
Peptibodies Peptide-Fc fusion
proteins
(83)
Induction of
MDSC
differentiation
Vitamins ATRA
Vitamin A
Vitamin D3
Vitamin E
(69, 84–86)
Antibodies GR1 antibodies (87, 88)
Block in MDSC
development
N-Bisphophonates Zoledronic acid (21)
Multi-kinase
inhibitors
Sunitinib
Sorafenib
(89, 90)
JAK2/STAT3
inhibitors
Cucurbitacin B
JSI-124
(91, 92)
Blocking
antibodies
Anti IL-17 antibodies
Anti-glycan antibodies
(93–95)
Quinoline-3-
carboxamide
derivative
Tasquinimod (64, 96)
NO, nitric oxide; COX2, cyclooxygenase-2; NOHA, N-hydroxy-L-Arginine;
L-NAME, N(G)-nitro-L-arginine methyl ester; ROS, reactive oxygen species; IDO,
indoleamine 2,3-dioxygenase; HSP90, heat shock protein 90; 17-DMAG, 17-
dimethylaminoethylamino-17-demethoxygeldanamycin; ATRA, all-transretinoic
acid.
cell suppression. IDO locally depletes tryptophan and gener-
ates tryptophan metabolites including kynurenine resulting in
reduced proliferation of CD4+ T cells, CD8+ T cells, and
NK cells (97). IDO activity has been correlated with increased
immunosuppressive activity in MM patients and can be targeted
by d,l-1-methyl-tryptophan (80). ROS secretion also contributes
to the immunosuppressive action of MDSC and is caused by
the increase in NADPH oxidase activity in granulocytic MDSC.
Increased ROS levels were observed in EL4 tumor-bearing mice
and could be targeted by a STAT3 inhibitor JSI-124 (91). Syn-
thetic triterpenoid Bardoxolone Methyl (CDDO-Me) also reduced
ROS and nitrotyrosine levels in EL4 mice, which was accom-
panied by an increased T cell response and reduced tumor
load (79). Although not tested in hematological malignancies,
cyclooxygenase-2 (COX2) inhibitors have also been described to
reduce MDSC numbers and their immunosuppressive function in
mesothelioma (78).
MDSC DEPLETION
The MDSC-depleting capacity of cytotoxic agents including 5-
fluorouracil (5FU) and gemcitabine has been explored in the EL4
murine lymphoma model (81). Both agents were able to deplete
MDSC in the spleen and tumor bed, with 5FU being the most
potent drug. Similar effects on granulocytic and monocytic sub-
populations could be observed. It has been demonstrated that
5FU exerted anti-tumor activities at least in part by elimination
of MDSC and the restoration of T cell specific immune responses.
Another compound, the HSP90 inhibitor 17-DMAG, was recently
tested in a murine sarcoma model and resulted in a reduced num-
ber of MDSC and regulatory T cells upon in vivo administration;
however, the underlying mechanism remains unknown (82).
Recently, peptide-Fc fusion proteins, named peptibodies, were
developed to target the MDSC population in vivo. Via a com-
petitive phage display platform MDSC specific peptibodies were
identified. The peptibodies were engineered to express the mouse
IgG2b Fc portion to enhance antibody-dependent cell-mediated
cytotoxicity (ADCC). Intravenous peptibody injection was able to
deplete blood, spleen, and intratumoral MDSC in distinct lym-
phoma models (A20, EG7, EL4). No effects on other immune
cells, including DC and lymphocytes (T, B, and NK cells), could be
detected. Importantly, peptibody treatment in EL4 tumor-bearing
mice delayed tumor growth in vivo as determined by tumor size
and tumor mass. In contrast to anti-GR1 specific antibodies, which
predominantly target the granulocytic population, peptibodies
were able to deplete both monocytic and granulocytic MDSC (83).
INDUCTION OF MDSC DIFFERENTIATION
Another mechanism to target the MDSC population is the induc-
tion of MDSC differentiation into mature myeloid cells with no
suppressive activities. MDSC differentiation can be triggered by
distinct vitamins including vitamin A, vitamin D3, or vitamin E
(84–86, 98). ATRA (all-transretinoic acid), a vitamin A metabo-
lite, induces the differentiation of monocytic MDSC in DC and
macrophages, and causes apopotosis of the granulocytic MDSC
population. As a consequence, ATRA improved immunotherapy
in distinct murine models (98).
Anti-GR1 antibodies are described to bind with a high affin-
ity to Ly6G molecules and have been extensively used to deplete
G-MDSC in tumor-bearing mice. In contrast, Ribechini et al.
demonstrated that anti-GR1 antibodies induced myeloid expan-
sion and upregulation of macrophage markers (F4/80, CD115) in
BM-derived MDSC. In addition, they observed increased STAT
phosphorylation (STAT1, STAT3, STAT5) by anti-GR1 antibody
treatment of BM cells in vitro. Protection of BM MO-MDSC
against apoptosis was correlated with increased expression of
the anti-apoptotic factor Mcl1. Despite the incapacity of MDSC
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depletion, anti-GR1 antibodies transiently decreased the immune-
suppressive activity of GR1high and GR1low subpopulations (87).
The effect of anti-GR1 antibodies was also investigated in EL4
tumor-bearing mice (88). In this murine lymphoma model, a
complete elimination of MDSC in the spleen and peripheral blood
was observed, but hepatic MDSC remained. Despite induction of
apoptosis of hepatic MDSC by anti-GR1 antibodies, the popu-
lation is immediately replaced and showed immunosuppressive
activities.
BLOCK IN MDSC DEVELOPMENT
IL-17 has been identified as an important factor in MDSC develop-
ment. IL-17R−/− EG7-OVA tumor-bearing mice (EL4 transfected
with the chicken ovalbumine gene) showed a lower MDSC num-
ber compared to WT mice (93). In addition, reduced arginase-1,
MMP9, and S100A8/9 expression was observed in IL-17R−/− com-
pared to WT MDSC. IL-17 neutralizing antibodies were able to
decrease tumor growth in WT mice indicating the importance
of IL-17 targeting strategies in cancer treatment (93). Besides
the effect on MDSC expansion, it has been demonstrated that
S100A8/S100A9 proteins are also involved in MDSC recruitment
and retention. Migration to the tumor site is promoted by the
binding of S100 proteins to carboxylated N-glycan receptors. The
anti-carboxylated glycan antibody mAbGB3.1 was able to reduce
MDSC numbers in the blood and secondary lymphoid organs
(99). Furthermore, mAbGB3.1 was able to block tumor cell prolif-
eration in colorectal cancer (94, 95). In addition, Tasquinimod, a
quinoline-3-carboxamide derivative, binds to S100A9 and blocks
the interaction with its ligands receptor of advanced glycation
end products (RAGE) and toll like receptor 4 (TLR4). It has been
demonstrated that Tasquinimod reduced MDSC accumulation,
modulated local tumor immunity, and reduced tumor growth and
metastasis (64, 96).
As previously mentioned, the N -bisphosphonate zoledronic
acid reduced MDSC number and osteoclast formation in MM
disease (21). JAK2/STAT3 inhibitors (JSI-124 and Cucurbitacin
B) (91, 92) and multi-kinase inhibitors (Sunitinib and Sorafenib)
were also described to reduce MDSC levels (89, 90). Cucur-
bitacin B induces differentiation and maturation of DC (92).
Sunitinib treatment resulted in 50% reduction of peripheral blood
MDSC, reduced regulatory T cell number, and enhanced Th1
response in renal cell cancer patients (89). Sorafenib, another
multi-kinase inhibitor, decreased immunosuppressive cell types
in hepatocellular carcinoma (90).
MDSC IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
Hematopoietic SCTs have been used as a frequent therapy in
blood and BM cancers. However, infections and graft-versus-
host disease (GVHD) remain a major cause of mortality. In
order to reduce GVHD in allogeneic hematopoietic stem cell
transplantation (HSCT), it might be of interest to expand the
MDSC population and reduce allogeneic donor T cell activ-
ity in patients. Interestingly, it was found that MDSC num-
bers were higher in SHIP−/− mice displaying a reduced GVHD
compared to WT mice (100). In subsequent studies, it was
demonstrated that administration of MDSC together with BM
transplantation was able to significantly inhibit GVHD lethality
and was associated with a decreased proliferation and activa-
tion of donor T cells (101, 102). Furthermore, arginase-1 is an
important contributor to this effect since administration of a
PEGylated form of Arginase-1 could reduce GVHD lethality. In
preclinical models, it is described that during BM chimerism
monocytic and polymorphonuclear MDSC subsets with allore-
active T cell suppressive capacity have expanded (103). Inter-
estingly, phenotypical and functional studies demonstrated an
expansion of similar subsets, MO-MDSC (CD14+CD15−) and
G-MDSC (CD14−CD15+), in peripheral blood derived from G-
CSF-treated stem cell donors (103). Furthermore, an increased
frequency of T cell suppressive CD14+ HLA-DRlow/neg cells was
found in allo-HSCT patients after transplantation (26) (Table 1).
All these studies indicate that MDSC might have a beneficial
role in preventing GVHD and thus can have important clinical
implications.
PERSPECTIVES
The past years, extensive research has been performed on MDSC
in hematological malignancies. Despite the increasing knowl-
edge, many questions remain concerning the role of distinct
MDSC subtypes and mechanisms inducing MDSC expansion
and/or survival. MDSC differentiation stages toward TAM and
tumor-associated neutrophils also remain an unexplored field. In
addition, caution in the interpretation of murine experiments is
needed. Subcutaneous tumor models (including EG7, EL4, A20)
have the major limitation of a localized tumor growth and are
less representative because of the lack of an appropriate tumor
microenvironment.
Immune modulating agents, especially in combination with
other drugs, have significantly improved the outcome of patients
with relapsed/refractory MM and lymphoma (104, 105). How-
ever, cancer-induced accumulation of immunosuppressive cell
types including MDSC, TAM, and regulatory T cells coun-
teract this immune reaction. In order to improve the effi-
cacy of immune modulating drugs and to induce a durable
anti-tumor immune response, MDSC targeting could be of
great interest. Recently, Tadalafil, a PDE5-inhibitor, induced a
long-term anti-myeloma immune and clinical response in a
patient with end-stage relapsed/refractory MM (76). In addi-
tion, MM-induced osteolytic bone lesions could be reduced by
MDSC targeting strategies. Currently, no specific MDSC tar-
geting agents are available and hamper further investigation.
Development of new agents and combination studies of MDSC
targeting drugs (e.g. 5FU, anti-GR1) with currently used ther-
apy for MM, lymphoma and leukemia are necessary in the
future.
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